These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 28567478)

  • 21. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
    Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
    Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Maris JM; Kolb EA; Gorlick R; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Nov; 62(11):1897-905. PubMed ID: 26154614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
    Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
    Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A; Northcote PT; Miller JH
    Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.
    Risinger AL; Jackson EM; Polin LA; Helms GL; LeBoeuf DA; Joe PA; Hopper-Borge E; Ludueña RF; Kruh GD; Mooberry SL
    Cancer Res; 2008 Nov; 68(21):8881-8. PubMed ID: 18974132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.
    Rai A; Kapoor S; Naaz A; Kumar Santra M; Panda D
    Biochem Pharmacol; 2017 May; 132():38-47. PubMed ID: 28242250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
    Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
    Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
    Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ
    J BUON; 2012; 17(2):284-90. PubMed ID: 22740207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
    Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
    Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
    Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
    ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.
    Galmarini CM; Kamath K; Vanier-Viornery A; Hervieu V; Peiller E; Falette N; Puisieux A; Ann Jordan M; Dumontet C
    Br J Cancer; 2003 Jun; 88(11):1793-9. PubMed ID: 12771997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
    Pabla N; Sparreboom A
    Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.